TABLE 2.

Results of pairwise meta-analyses for the MMSE score.

Comparative	Reference medications	Number of studies	Number of controls	Number of patients	MD/OR	95% CI	I2	p
Donepezil	Placebo	7	390	396	2.21	[-0.47, 4.88]	0	0.001
MEM	Placebo	9	284	396	1.05	[0.18, 1.79]	0	0.001
RIV	Placebo	9	326	404	0.32	[-0.61, 1.35]	0	0.009
Acupuncture	Placebo	6	338	339	1.99	[1.09, 2.88]	0	0.0001
NBP	Placebo	7	264	264	4.89	[4.14, 5.63]	0	0.0001
Nimodipine	Placebo	2	32	33	2.13	[1.52, 2.75]	0	0.0001
Citicoline	Placebo	2	82	86	1.63	[1.28, 1.98]	NA	0.0001
NBP + Oxiracetam	Placebo	6	264	265	1.26	[0.97, 1.56]	0	0.0001
TCM	Placebo	6	139	141	1.30	[0.89, 6.55]	0	0.0001
Cell therapies	Placebo	4	136	137	2.80	[1.24, 4.37]	0	0.0004
Oxiracetam	Placebo	4	101	101	1.34	[0.88, 1.8]	0	0.01
Antipatient angents	Placebo	1	40	40	1.73	[0.91,3.29]	0	0.08
Oxygen	Placebo	24	931	943	4.00	[3.28, 4.73]	0	0.00001
Olacetam	Placebo	42	1864	1851	6.09	[4.55, 7.62]	0	0.01

CI, confidence interval; MD, mean difference; OR, risk ratio; I², heterogeneity; MEM, memantine; RIV, rivastigmine; NBP, DL-3-n-Butylphthalide.